A Neutral Effect of Metformin Treatment on Macroprolactin Content in Women with Macroprolactinemia

R. Krysiak; W. Szkróbka; B. Okopień

doi:10.1055/s-0042-117718

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2017; 125(04): 223-228
DOI: 10.1055/s-0042-117718

Article

A Neutral Effect of Metformin Treatment on Macroprolactin Content in Women with Macroprolactinemia

R. Krysiak

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

,

W. Szkróbka

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

,

B. Okopień

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

› Author Affiliations

Abstract

Background: Metformin decreases serum levels of monomeric prolactin. No previous study has investigated the effect of metformin on macroprolactin content in patients with macroprolactinemia.

Methods: We studied three age-, sex- and weight-matched groups of patients: 15 women with monomeric prolactin, 12 women with macroprolactin, as well as 15 women with normal prolactin levels. Because of coexisting 2 diabetes or prediabetes all patients were treated with metformin (1.7–3 g daily). Plasma lipids, glucose homeostasis markers, as well as serum levels of prolactin and macroprolactin were assessed at baseline and after 4 months of metformin treatment.

Results: As expected, metformin reduced plasma glucose and triglycerides, as well as improved insulin sensitivity in all treatment groups. Moreover, the drug reduced post-polyethylene glycol prolactin levels and tended to reduce pre-polyethylene glycol prolactin levels in women with monomeric prolactin but not in women with macroprolactinemia and women with normal prolactin levels.

Conclusion: The obtained results indicate that metformin has a negligible effect on macroprolactin levels.

Key words

hyperprolactinemia - macroprolactin - monomeric prolactin - insulin resistance

Full Text

References

References
1 American Diabetes Association . Approaches to glycemic treatment. Diabetes Care 2016; 39 (Suppl. 01) S52-S59
2 Genuth S. The UKPDS and its global impact. Diabet Med 2008; 25 (Suppl. 02) 57-62
3 Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006; 91: 225-227
4 Cappelli C, Rotondi M, Pirola I et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 2009; 32: 1589-1590
5 Isidro ML, Penín MA, Nemiña R et al. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007; 32: 79-82
6 Morteza Taghavi S, Rokni H, Fatemi S. Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res 2011; 8: 47-48
7 Krysiak R, Okopień B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism. J Clin Pharmacol 2015; 55: 45-49
8 Krysiak R, Okopień B. Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin Endocrinol 2011; 75: 404-406
9 Oride A, Kanasaki H, Purwana IN et al. Effects of metformin administration on plasma gonadotropin levels in women with infertility, with an in vitro study of the direct effects on the pituitary gonadotrophs. Pituitary 2010; 13: 236-241
10 Genazzani AD, Battaglia C, Malavasi B et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 1114-1119
11 Billa E, Kapolla N, Nicopoulou SC et al. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol 2009; 25: 427-434
12 Krysiak R, Okrzesik J, Okopień B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 2014; 49: 242-249
13 Banaszewska B, Pawelczyk L, Spaczynski RZ et al. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011; 96: 3493-3501
14 Krysiak R, Kowalcze K, Szkrobka W et al. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J Intern Med 2016; 30: 94-98
15 Schiettecatte J, Van Opdenbosch A, Anckaert E et al. Immunoprecipitation for rapid detection of macroprolactin in the form of prolactin-immunoglobulin complexes. Clin Chem 2005; 51: 1746-1748
16 Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005; 42 (Pt 3) 175-192
17 Fahie-Wilson M, Smith TP. Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab 2013; 27: 725-742
18 Gulcelik NE, Usman A. Macroprolactinaemia in diabetic patients. Neuro Endocrinol Lett 2010; 31: 270-274
19 Sari F, Sari R, Ozdem S et al. Serum prolactin and macroprolactin levels in diabetic nephropathy. Clin Nephrol 2012; 78: 33-39
20 Krysiak R, Kowalska B, Szkróbka W et al. The effect of oral contraception on macroprolactin levels in women with macroprolactinemia: a pilot study. Pharmacol Rep 2015; 67: 854-857
21 Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V et al. Sexual function and depressive symptoms in young women with elevated macroprolactin content: a pilot study. Endocrine 2016 [Epub ahead of print]
22 Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005; 62: 633-643
23 Olukoga AO. Macroprolactinemia is clinically important. J Clin Endocrinol Metab 2002; 87: 4833-4834
24 Vallette-Kasic S, Morange-Ramos I, Selim A et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002; 87: 581-588
25 Kasum M, Pavičić-Baldani D, Stanić P et al. Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol 2014; 183: 28-32
26 Krysiak R, Kowalska B, Szkróbka W et al. A neutral effect of testosterone therapy on macroprolactin content in men with macroprolactinemia and late-onset hypogonadism. Pharmacol Rep 2016; 68: 139-143
27 Krysiak R, Kowalska B, Szkróbka W et al. The association between macroprolactin levels and vitamin D status in premenopausal women with macroprolactinemia: a pilot study. Exp Clin Endocrinol Diabetes 2015; 123: 446-450
28 Mounier C, Trouillas J, Claustrat B et al. Macroprolactinaemia associated with prolactin adenoma. Hum Reprod 2003; 18: 853-857
29 Tamer G, Telci A, Mert M et al. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine 2012; 41: 138-143
30 Christin-Maître S, Delemer B, Touraine P et al. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 2007; 68: 106-112
31 Hattori N, Adachi T, Ishihara T et al. The natural history of macroprolactinaemia. Eur J Endocrinol 2012; 166: 625-629
32 Krysiak R, Okopień B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol 2015; 116: 251-256